Literature DB >> 19366393

Impact of audit and feedback on antipsychotic prescribing in schizophrenia.

Amanda Wheeler1, Verity Humberstone, Elizabeth Robinson, Janie Sheridan, Peter Joyce.   

Abstract

OBJECTIVE: To examine the impact of audit and feedback on antipsychotic prescribing for schizophrenia outpatients over 4.5 years.
METHODS: Clinical files in three mental health services caring for outpatients in Auckland, New Zealand were reviewed at two time-points (March 2000, October 2004). After the first audit, feedback was provided to all three services. Baseline prescribing variations between services were found for antipsychotic combinations and second-generation antipsychotic (SGA) prescribing, in particular clozapine. In two services audit and feedback continued with two interim reviews (October 2001, March 2003). Specific feedback and interventions targeting clozapine use were introduced in both services. No further audit or feedback occurred in the third service until the final audit. Data were collected (patient characteristics, diagnosis, antipsychotic treatment) and analysed at each audit.
RESULTS: Three prescribing variables (antipsychotic monotherapy, SGA and clozapine use) were consistent with practice recommendations at the final audit (85.7%, 82.7% and 34.5% respectively) and had changed in the desired direction for all three services over the 4.5 years. At baseline there were differences between the three services. One service had baseline prescribing variables closest to recommendations, was actively involved in audit, and improved further. The second service, also actively involved in audit had baseline prescribing variables further from recommendations but improved the most. The service not involved in continuing audit and feedback made smaller changes, and SGA and clozapine use at endpoint were significantly lower despite at baseline being comparable to the service which improved the most.
CONCLUSIONS: This study found audit and feedback to be an effective intervention in closing the gap between recommended and routine clinical practice for antipsychotic prescribing in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366393     DOI: 10.1111/j.1365-2753.2008.01032.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  7 in total

1.  Clozapine: a distinct, poorly understood and under-used molecule.

Authors:  Ridha Joober; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

2.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 3.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

Review 4.  Feedback as a strategy to change behaviour: the devil is in the details.

Authors:  Elaine L Larson; Sameer J Patel; David Evans; Lisa Saiman
Journal:  J Eval Clin Pract       Date:  2011-11-29       Impact factor: 2.431

Review 5.  Worldwide Differences in Regulations of Clozapine Use.

Authors:  Jimmi Nielsen; Corina Young; Petru Ifteni; Taishiro Kishimoto; Yu-Tao Xiang; Peter F J Schulte; Christoph U Correll; David Taylor
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

6.  A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Authors:  Robert O Cotes; A Umair Janjua; Beth Broussard; David Lazris; Ayesha Khan; Yunshen Jiao; Sarah L Kopelovich; David R Goldsmith
Journal:  Community Ment Health J       Date:  2021-05-29

7.  Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.

Authors:  Sara S McMillan; Sara Jacobs; Louise Wilson; Theo Theodoros; Gail Robinson; Claire Anderson; Gabor Mihala; Amanda J Wheeler
Journal:  BMC Psychiatry       Date:  2017-04-13       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.